{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:09:23Z","timestamp":1768882163894,"version":"3.49.0"},"reference-count":24,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T00:00:00Z","timestamp":1528848000000},"content-version":"unspecified","delay-in-days":163,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Technol Assess Health Care"],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:sec id=\"S026646231800034X_sec_a1\"><jats:title>Objectives:<\/jats:title><jats:p>It is not yet established the advantages between amphotericin B lipid complex (ABLC) and liposomal (L-AmB) in patients with invasive fungal infections refractory to usual doses of conventional AmB (d-AmB), previous renal impairment, or unacceptable d-AmB renal toxicity. This systematic review aims to compare ABLC and L-AmB effectiveness and safety outcomes in these subgroups of patients.<\/jats:p><\/jats:sec><jats:sec id=\"S026646231800034X_sec_a2\" sec-type=\"methods\"><jats:title>Methods:<\/jats:title><jats:p>The search was performed on Medline, Cochrane Library, EMBASE, and LILACS databases. Inclusion criteria: treatment comparing L-AmB with ABLC; patients who had (i) refractory infection after being treated with d-AmB, (ii) previous renal impairment, or (iii) unacceptable d-AmB toxicity. Two investigators independently screened the search results, assessed trial quality, and extracted data. A total of 1,054 articles were identified in the literature. Among those, eleven were selected for full-text reading and five met the inclusion criteria.<\/jats:p><\/jats:sec><jats:sec id=\"S026646231800034X_sec_a3\" sec-type=\"results\"><jats:title>Results:<\/jats:title><jats:p>The five articles included reported on four separate observational studies. Overall, no significant difference was found in clinical relevant outcomes as new-onset dialysis, length of hospital stay, or mortality when comparing both lipid formulations. The studies reported a trend toward lower nephrotoxicity in patients treated with L-AmB. However, the results were imprecise and heterogeneous and the studies presented important methodological biases.<\/jats:p><\/jats:sec><jats:sec id=\"S026646231800034X_sec_a4\" sec-type=\"conclusion\"><jats:title>Conclusions:<\/jats:title><jats:p>The studies included in this systematic review pointed toward less nephrotoxicity events in the L-AmB group. However, due to low quality of evidence and no statistically significant differences in other clinical relevant outcomes, there is no definitive evidence of overall superiority in effectiveness or safety outcomes regarding one lipid formulation or another in this population subgroup.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s026646231800034x","type":"journal-article","created":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T05:59:54Z","timestamp":1528869594000},"page":"343-351","source":"Crossref","is-referenced-by-count":12,"title":["COMPARATIVE EFFECTIVENESS AND SAFETY BETWEEN AMPHOTERICIN B LIPID-FORMULATIONS: A SYSTEMATIC REVIEW"],"prefix":"10.1017","volume":"34","author":[{"given":"Luiza Raquel","family":"Grazziotin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila Beltrami","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Angelica Pires","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2018,6,13]]},"reference":[{"key":"S026646231800034X_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.04.001"},{"key":"S026646231800034X_ref14","first-page":"e329","article-title":"Reduction of invasive fungal infections among cancer patients with chemotherapy-induced neutropenia after protective environment implementation may save costs in a developing country: A quasi-experimental study","volume":"3","author":"Stoll","year":"2016","journal-title":"Int J Infect."},{"key":"S026646231800034X_ref6","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.suppl_1.37"},{"key":"S026646231800034X_ref24","doi-asserted-by":"publisher","DOI":"10.1017\/S026646230505035X"},{"key":"S026646231800034X_ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-013-0072-7"},{"key":"S026646231800034X_ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181e9441b"},{"key":"S026646231800034X_ref18","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12283"},{"key":"S026646231800034X_ref5","doi-asserted-by":"publisher","DOI":"10.1590\/S1413-86702006000200005"},{"key":"S026646231800034X_ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0069-4"},{"key":"S026646231800034X_ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12802"},{"key":"S026646231800034X_ref10","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969030-00010"},{"key":"S026646231800034X_ref1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki218"},{"key":"S026646231800034X_ref2","first-page":"215","article-title":"Changing epidemiology of classical and emerging human fungal infections: A review","volume":"5","author":"Abu-Elteen","year":"2012","journal-title":"Jordan J Biol Sci."},{"key":"S026646231800034X_ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05763.x"},{"key":"S026646231800034X_ref4","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080325"},{"key":"S026646231800034X_ref8","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097650"},{"key":"S026646231800034X_ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-005-1955-9"},{"key":"S026646231800034X_ref16","unstructured":"Drugs Price list Brazil: National Agency of Sanitary Vigilance; 2017. http:\/\/portal.anvisa.gov.br\/consulta-lista-de-preco-de-medicamento (accessed May 12, 2018)."},{"key":"S026646231800034X_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"S026646231800034X_ref19","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1010080"},{"key":"S026646231800034X_ref20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23311"},{"key":"S026646231800034X_ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2007.01483.x"},{"key":"S026646231800034X_ref7","doi-asserted-by":"publisher","DOI":"10.1086\/317451"},{"key":"S026646231800034X_ref23","doi-asserted-by":"publisher","DOI":"10.1086\/319211"}],"container-title":["International Journal of Technology Assessment in Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S026646231800034X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T06:12:32Z","timestamp":1561356752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S026646231800034X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"alternative-id":["S026646231800034X"],"URL":"https:\/\/doi.org\/10.1017\/s026646231800034x","relation":{},"ISSN":["0266-4623","1471-6348"],"issn-type":[{"value":"0266-4623","type":"print"},{"value":"1471-6348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}